On June 16, 2023, Coherus BioSciences, Inc. and Surface Oncology, Inc. announced that they have entered into a definitive merger agreement, where, at the closing, Coherus will acquire Surface Oncology, a clinical-stage immuno-oncology (I-O) company developing next-generation immunotherapies that target the tumor microenvironment. Coherus’ Chairman and Chief Executive Officer said that “[t]his transaction is well-timed
More Posts
Celltrion Confirms Bioequivalence For CT-P39 Against Xolair In Interim Results Of Phase 3 Study
Celltrion’s Anticancer Biosimilar Debuts in Japan
Amneal Launches RELEUKO (filgrastim-ayow) in the United States
Request for Comments on USPTO Initiatives To Promote Generic Drug and Biosimilar Competition
Genentech and Samsung Bioepis Settle Bevacizumab Biosimilar Patent Dispute
Sandoz Announces New Global “Act4Biosimilars” Initiative
Samsung Biologics Completes Full Acquisition of Samsung Bioepis
OcyonBio Announces Biosimilar Solutions to Begin GMP Manufacturing in Puerto Rico
FDA Accepts Samsung Bioepis’ and Organon’s sBLA for their Citrate-Free, High-Concentration HUMIRA (Adalimumab) Biosimilar Candidate
Subscribe: Subscribe via RSS
Blogs
Firm/Org